QualityStocks.net News – Unigene Laboratories Inc. (UGNE.OB) CEO Featured in Globally Distributed Biotechnology Publication

We would like to highlight Unigene Laboratories Inc. (OTCBB: UGNE). The company is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical^®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005.

In the company’s recent news,

Unigene Laboratories Inc. announced Warren P. Levy, Ph.D., CEO and president of Unigene, recently contributed a byline story in two leading pharmaceutical publications. The article, titled “Focusing on the Task of Reinventing Peptide Drugs; Unigene Has Introduced an Enzyme-Based Assay for the Discovery of Amidated Peptides,” emphasizes the importance of peptides in pharmaceutical research.

The article was featured in Genetic Engineering & Biotechnology News (GEN), the most widely read biotechnology publication in the world, and Pharmaceutical Formulation & QualityMagazine (PFQ), a health care journal with national circulation.

“Unigene’s technologies may enable the introduction of several oral peptide hormone drugs for administration in chronic osteoporosis and diabetes,” Dr. Levy stated. “While certain individual development projects are early stage, the trend is positive and the possibilities are plentiful. There has never been a more exciting time to be involved in peptide pharmaceutical development. Oral delivery methods have changed the paradigm for peptide drugs irrevocably - and for the better.”

In the article, Dr. Levy highlighted the company’s developments of a new enzyme-based assay for the discovery of amidated peptides, which could help identify low-concentration peptide hormones expected to open the door for the discovery of novel, biologically active peptides suitable for pharmaceutical development.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.